Dear all
thanks to Johanna we were also made aware that the new
examination guidance is online:
with track changes:
https://www.epo.org/law-practice/legal-texts/guidelines/guidelines-preview.html
final:
https://www.epo.org/law-practice/legal-texts/guidelines.html
general overview:
https://www.epo.org/law-practice/legal-texts/official-journal/2021/01/a6.html
I attach the relevant chapter on patentability with track changes (I guess no German version is available).
it is made clear that rule 28(2) has not be applied to
applications filed before July 2017. in this context, also the
role of the disclaimer is defined in more detail.
!! on page 51 random mutations are considered:
an very lousy example for patentable inventions was deleted. Very
good. Further clarification was added:
A mutant of a plant carrying a heritable exchange in a nucleotide
sequence effected by technical means, e.g. UV mutagenesis or
CRISPR/Cas with the proviso that the plant is not exclusively
obtained
by means of an essentially biological process (EBP).
the second part (now added) of the sentence means that even it
mutagenesis is applied, the plant still might be derived from
essentially biological processes. This could mean that the patent
applicant has to show that the claims are in accordance with G2/07
and G1/08 (direct insertion of a trait) and it is not enough to
show that mutagenesis was applied.
To further discuss this issue I would like to give two examples:
in the case of herbicide resistant plants derived from random
mutations it might be sufficient to treat them with the herbicide
to identify the desired traits (patentable)
in case of plants with resistant to downy mildew it might be
necessary to perform (after mutatgenesis) further crossing and
selection to derive to the desired (quantitative) trait.
These examples show how these new guidance might become applied.
this would mean a step ahead: So far, each application of
mutagenesis was sufficient to overcome rule 28 (2). Now only some
plants might escape.
But still not all methods for conventional breeding would be
excluded.
There is another possibility how this additional half sentence
might be used (and made worthless): The EPO could decide to simply
demand a disclaimer, leaving it completely open what exactly is
patentable or excluded.
!! on page 52, living cells are excluded if derived from relevant
plants or animals - this seems to a success of our work.
Summary: Some progress was made. It is hard to say if we have
chances to reach better decisions by the Admin Council if we
follow our current approach. The alternative would be to say: We
now see that based on latest documents, final clarity only can be
achieved by a change of law. This also might mean we still could
use patents as granted before July 2017 to raise pressure - the
debate would no longer just concern rule 28(2). This also might
help to move ahead the Admin Council to provide further
clarifications.
We have to discuss this next week during our phone call. I also
will continue to think about and might have improved analysis next
week.
cheers
Christoph